Likewise, Formoterol, targeting ADRB2 (Beta-2 adrenergic receptor), etc., is an inhaled beta-2 agonist that was approved by the FDA in 2001 for the treatment of chronic obstructive pulmonary disease (COPD) and asthma [110]. Here, ADRB2 is linked to asthma.